GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Research & Development

Zenith Capital (Zenith Capital) Research & Development : $ Mil (TTM As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Zenith Capital's Research & Development for the three months ended in . 20 was $0.00 Mil. Zenith Capital does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in . 20.


Zenith Capital Research & Development Historical Data

The historical data trend for Zenith Capital's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Research & Development Chart

Zenith Capital Annual Data
Trend
Research & Development

Zenith Capital Quarterly Data
Research & Development

Zenith Capital Research & Development Calculation

This is the expense the company spent on research and development.


Zenith Capital  (OTCPK:ZHCLF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Zenith Capital Research & Development Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenith Capital (Zenith Capital) Business Description

Traded in Other Exchanges
N/A
Address
300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1
Website
Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines